Literature DB >> 30506759

Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.

Michael D Walsh1, Harindra Jayasekara2,3,4,5, Alvin Huang2,4, Ingrid M Winship6,7, Daniel D Buchanan2,4,6.   

Abstract

BACKGROUND/
OBJECTIVES: Loss of expression of mismatch repair (MMR) proteins is frequently observed in sebaceous skin lesions and can be a herald for Lynch syndrome. The aim of this study was to identify clinico-pathological predictors of MMR deficiency in sebaceous neoplasia that could aid dermatologists and pathologists in determining which sebaceous lesions should undergo MMR immunohistochemistry (IHC).
METHODS: An audit of sebaceous skin lesions (excluding hyperplasia) where pathologist-initiated MMR IHC was performed between January 2009 to December 2016 was undertaken from a single pathology practice identifying 928 lesions from 882 individuals. Lesions were further analysed for differences in gender, age at diagnosis, lesion type and anatomic location, stratified by MMR status.
RESULTS: The 882 individuals (67.7% male) had a mean (SD) age of diagnosis of 68.4 ± 13.3 years. Nearly two-thirds of the lesions were sebaceous adenomas, with 82.6% of all lesions occurring on the head and neck. MMR deficiency, observed in 282 of the 919 lesions (30.7%), was most common in sebaceous adenomas (210/282; 74.5%). MMR-deficient lesions occurred predominantly on the trunk or limbs (64.7%), compared with 23.2% in head or neck (P < 0.001). Loss of MSH2 and MSH6 protein expression was most frequent pattern of loss (187/281; 66.5%). The highest AUC for discriminating MMR-deficient sebaceous lesions from MMR-proficient lesions was observed for the ROC curve based on subgroups defined by type and anatomic location of the sebaceous lesion (AUC = 0.68).
CONCLUSION: The best combination of measured clinico-pathological features achieved only modest positive predictive values, sensitivity and specificity for identifying MMR-deficient sebaceous skin lesions.
© 2018 The Australasian College of Dermatologists.

Entities:  

Keywords:  Lynch syndrome; Muir-Torre syndrome; mismatch repair deficiency; mismatch repair immunohistochemistry; sebaceoma; sebaceous adenoma; sebaceous carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30506759     DOI: 10.1111/ajd.12958

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

Review 2.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

3.  Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma.

Authors:  Michał Kunc; Anna Gabrych; Bartłomiej Rękawiecki; Adam Gorczyński; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2020-03-30

4.  A rare concurrence of Muir-Torre-associated sebaceous carcinoma in the setting of a lipedematous scalp.

Authors:  Allison Shanks; Jake Laun; Amanda Holstein; Saksham Varshney; Jane Messina; Carl Wayne Cruse
Journal:  Case Reports Plast Surg Hand Surg       Date:  2020-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.